Company news
Replimune Group, Inc. news in 2021
Replimune Group, Inc.'s news releases, calls and decks from 2021, newest first.
Replimune Appoints Christy Oliger to its Board of Directors
December 1, 2021
Replimune Provides Updated Data from RP2 at the 2021 Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
November 11, 2021
Replimune Announces Presentations at the 2021 Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
September 30, 2021
Replimune to Present at the William Blair Biotech Focus Conference 2021
July 6, 2021
Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expand the Development of RP2/3 Beyond Phase 1
June 2, 2021
Replimune Reports Fiscal Fourth Quarter and Year-Ended 2021 Financial Results and Provides Corporate Update
May 19, 2021
Replimune Appoints Tanya Lewis as Chief Development Operations Officer
May 9, 2021
Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination with Libtayo® (cemiplimab) for the Treatment of CSCC & Evaluating RP1 in Combination with Opdivo® (nivolumab) in anti-PD1 Failed Melanoma
May 4, 2021
Replimune to Host Virtual Investor Event on June 3, 2021
April 27, 2021
Replimune Appoints Genentech Global Oncology Franchise Head Sushil Patel, Ph.D. as Chief Commercial Officer
April 20, 2021
Replimune to Present New Biomarker & Pre-clinical Data for Lead Oncolytic Immunotherapy Programs at the 2021 American Association for Cancer Research Annual Meeting
April 11, 2021
Replimune to Present at the American Association for Cancer Research Annual Meeting 2021
March 10, 2021
Replimune to Present at the SVB Leerink 10th Annual Global Healthcare Conference
February 17, 2021
Replimune Provides 2020 Year End Review and Overview of Expected 2021 Milestones
January 10, 2021
Replimune to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 5, 2021
Replimune Announces First Patient Dosed with RP3 in a Phase 1 Clinical Trial in Patients with Advanced Solid Tumors
January 4, 2021